Lee HF, et al. - Using data from the Taiwan National Health Insurance Research Database, the efficacy of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in end stage renal disease (ESRD) subjects were investigated in this nationwide retrospective cohort study. This investigation recruited ESRD patients from January 1997 to December 2011. Propensity score matching provided two study groups (ACEI/ARB users vs nonusers) balanced in sample size with similar comorbidities and prescriptions. Findings revealed that the connection of ACEIs/ARBs use with low mortality risk was noted in all examined subgroups. Data reported that ESRD subjects using ACEIs/ARBs had a lower risk of cardiovascular death and all-cause mortality than nonusers did.